Anthony C. Kuhlmann, Ph.D.

Of Counsel
Intellectual Property

Dr. Anthony Kuhlmann, of counsel in the Orange County office, is a member of the Intellectual Property Group.

Dr. Kuhlmann is a registered patent attorney concentrating his practice in the area of patent prosecution and strategic client counseling in the life sciences with particular experience in biotechnology, pharmaceuticals and medical diagnostics.

Dr. Kuhlmann has an in-depth understanding of drug development, research and toxicology, as well as in the development of medical diagnostics. Dr. Kuhlmann uses this unique skill set to advise in-house counsel and company executives on the development of worldwide patent portfolios and the integration of intellectual property and business assets.

Dr. Kuhlmann's experience also includes conducting IP due diligence for corporate transactions and acquisitions, negotiating licensing agreements, performing patentability, infringement and validity analyses, and authoring opinion letters.

Prior to law school, Dr. Kuhlmann was an investigator for Vertex Pharmaceuticals, Inc., where he established an animal model of Parkinson's disease for efficacy and toxicity studies. Dr. Kuhlmann has co-authored numerous scientific publications in the fields of neurotoxicology and neuropathology. His publications appear in journals including Journal of Neurochemistry, Neuroscience Letters, Brain Research and Toxicological Sciences.

Anthony Kuhlmann, Ph.D.
Speeches
  • OBR-Gene Patenting Debate. Oxbridge Biotech Roundtable, San Diego, CA, September 2013.
  • Recent Developments in Biotechnology and Pharmaceutical Patent Law; TIDES Conference: Oligonucleotide and Peptide Technology and Product Development, Las Vegas, NV, May 2008.
  • Future Trends in the Convergence of Drug Development and Medical Devices; Sino-American Biotechnology & Pharmaceutical Association Third Annual Biomedical Forum, Huntington Beach, CA, March 2008.
  • Latest Thinking on Attacking/Defending Patent Rights in the U.S. Pharmaceutical and Biotechnology Markets; Henry Stewart Conference Studies, San Francisco, CA, Sept. 2005.
  • IP Due Diligence and Auditing: Evolving Standards, SOX Compliance, Risk Management; Legal Publishing Group of Stafford Publications, June 2005.
Select Publications
  • "A Troubling Trend for Personalized Medicine Patents," Law360, December 4, 2012.
  • "Standards of Review: Implications for Patent Challengers," Bloomberg BNA, November 30, 2012.
  • "Inventions in Unpredictable Fields — Not Always Unobvious," Law360, November 7, 2012.
  • "Section 102: A Dead Letter for Qualifying Claims," Law360, June 25, 2012.
  • N-methyl-D-aspartate receptor subunit changes are associated with lead-induced deficits of long-term potentiation and spatial learning. Neurosci. 99 (2000) 233-42.
  • Cellular and subcellular localization of the peripheral benzodiazepine receptor after trimethyltin neurotoxicity. J. Neurochem. 74 (2000) 1694-1704.
  • Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity. Toxicol. Sci. 48 (1999) 107-16.
  • Maternal lead exposure impairs spatial learning in adult rats. Neurosci. Lett. 233 (1997) 281-8.
  • The peripheral benzodiazepine receptor is a sensitive indicator of domoic acid neurotoxicity. Brain Res. 751 (1997) 263-9.
  • Intrahippocampal administration of lead impairs performance of rats in the Morris water maze. Pharmacol. Biochem. Behav. 57 (1997) 271-9.
  • Age-dependent effects of developmental lead exposure on performance in the Morris water maze. Pharmacol. Biochem. Behav. 57 (1997) 271-9.
  • Enhanced expression of peripheral benzodiazepine receptors in the rat brain: a potential biomarker of chemical-induced neurotoxicity. Neurotoxicol. 16 (1995) 441-50.
Admitted In
  • California
  • Massachusetts
Court Admissions
United States District Court
  • Southern District of California
  • District of Massachusetts
United States Patent and Trademark Office

    Education
    • J.D., cum laude, Suffolk University Law School, 2004
    • Ph.D., Phi Beta Kappa, Neurotoxicology and Neuropathology, Johns Hopkins Bloomberg School of Public Health, 1999
    • B.Sc., highest honors, Toxicology, University of Guelph, 1993

    Please do not include any confidential, secret or otherwise sensitive information concerning any potential or actual legal matter in this e-mail message. Unsolicited e-mails do not create an attorney-client relationship and confidential or secret information included in such e-mails cannot be protected from disclosure. Orrick does not have a duty or a legal obligation to keep confidential any information that you provide to us. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

    By clicking "OK" below, you understand and agree that Orrick will have no duty to keep confidential any information you provide.

    OK
    Cancel